News About: Pharm. Industry
AstraZeneca headquarters selects Korea as one of most attracting investment countries
AstraZeneca Korea announced recently that Andrew Hauden, vice-president of AstraZeneca's Asia and Pacific regions, is slated to visit his third-time visit to Korea on April 21 following the previous visit of executive...
Pfizer Korea to focus on arthritis drugs as moneymaker
With Pfizer and Pharmacia combining operations on April 16, Pfizer Korea seems like to concentrate its sales on Bextra, Celebrex and Xalatan as new cash cow in the current downturn in the domestic pharmaceutical indus...
Tylenol 1st most favored brand among pain killersJanssen Korea's Tylenol is the first 2003 popular brand in analgesics among young couples in the 20s and 30s including newly-wed people, a recent survey showed.
Korea Market...
|
Hanmi wins Korean patent for egg-derived protein drug
Hanmi Pharm said on April 17 that it acquired a patent related to a core technology of producing a variety of high-price protein drugs from a transgenic hen (title: Multinfunctional embryonic reproduction cell line of...
SK3530, a new anti-impotence drug, under clinical studies in UK.
SK Chemical has developed SK3530, a new anti-impotence drug, jointly with In2Gen, a bio-venture company, and put its phase I clinical studies in England from April 23 after completing the pre-clinical studies on Mar. ...
Bulk drug as a stepping stone for further industrial leap.
The Korea New Drug R&D Association (hereinafter called Association) discussed in depth with Director Chang Joon-shik of the KFDA Drug Safety Bureau over the subject of the government support for the bulk drugs and its...
Korea Green Cross to inaugurate new life insurance company
Korea Green Cross Corporation, which was chosen as a final bidder of ailing Daeshin Life Insurance on March 26, is set to apply for the approval of a new company "Green Cross Life Insurance" to the Financial Superviso...
Marketing activities by domestic drug industries on alert.
The National Tax Service (NTS) may reinforce to impose a proof of burdens to the industry for their entertainment expenses, which triggered alert especially to the domestic pharmaceutical companies.
So far the NTS ...
MSD Korea receives good rating in corporate governance
MSD Korea said recently it has ranked 7th in terms of Korea's excellent corporate governance structure, according to a joint survey conducted by Asian Wall Street Journal, Maeil Business Newspaper and Hewitt Associate...
"Factive" inducing foreign capital investment.
For the first time in Korea "Factive", a novel antibiotic agent originally developed by LGCI, has been approved by the U. S. FDA, indicating its high technology of Korea for the new drug manufacture and the sustained ...
